Research
Lumateperone Brings Rapid Relief in Bipolar Mania
The Brief
- Lumateperone (Caplyta) rapidly improved symptoms of acute mania associated with bipolar I disorder, according to a phase III trial.
- The trial included 351 patients, with or without mixed features.
- Lumateperone showed superiority over placebo.
Why it matters
It reports phase III trial evidence for a faster-acting treatment for acute mania in bipolar I disorder, which matters to clinicians and researchers following psychiatric drug development.
Who’s affected
- Clinicians treating bipolar I disorder
- #psychiatry
- #bipolar-disorder
- #mania
- #clinical-trial
- #drug-development
(MedPage Today) -- Lumateperone (Caplyta) rapidly improved symptoms of acute mania associated with bipolar I disorder, a phase III trial showed. Among 351 patients with or without mixed features, lumateperone demonstrated superiority over placebo...